Abstract | Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
the scope of biomarkers to describing biological mol ecules. Such narrow definitions regard values obtained from imaging and other techniques as measurements of an underlying biomarker, rather than being biomarkers themselves. However, the current FDA-NIH definition takes a broader view. Earlier definitions also stated that biomarkers should have 'putative' diagnostic or prog nostic use 3 , although this requirement is no longer specified by FDA/NIH. Biomarkers must be measured, but can be numerical (quantitative) or categorical (either a quanti tative value or qualitative data; for definitions, see Supplementary information S1 (table) ). The use of both imaging biomarkers (IBs) and bio specimenderived biomarkers is widespread in oncology. In healthcare settings, biomarker uses include screen ing for disease; diagnosing and staging cancer; targeting surgical and radiotherapy treatments; guiding patient stratification; and predicting and monitoring therapeutic efficacy, and/or toxicity 4 . In research, biomarkers guide the development of investigational drugs as they progress along the pharmacological audit trail 5 , in which they can indicate the presence of drug targets, target inhibition, biochemical pathway modulation or pathophysiologi cal alteration by investigational drugs; drug therapeutic efficacy in specific groups of patients; and tracking of drug resistance 6 . The use of biomarkers has led to the identification of potentially successful drugs early in the developmental pipeline, thereby accelerating market approval for some therapies and enabling drug develop ers to reduce overall costs by identifying ineffective or toxic compounds at the earliest opportunity 5 . Despite some biomarkers being used extensively and others showing great potential 7, 8 , a surprisingly limited number of biomarkers guide clinical decisions [9] [10] [11] . Some putative cancer biomarkers are not adopted because they do not measure a relevant biological feature nor enable disease diagnosis or outcome prediction. In such cases, the biomarker is appropriately devalidated 12 . Many other promising biomarkers, however, are neither devalidated nor qualified for use in research or healthcare settings and, instead, are confined in the academic literature without real application owing to a lack of efficient and effective strategies for biomarker translation 13 . All biomarkers, including IBs, must cross two 'trans lational gaps' before they can be used to guide clinical decisions 14, 15 (FIG. 1) . Biomarkers that can reliably be used to test medical hypotheses cross the first gap becoming useful 'medical research tools'; if the biomarker crosses the second gap then it becomes a 'clinical decision making tool' . Some biomarkers that have only crossed the first translational gap are nevertheless highly useful in the development of therapies 5, 13 . Several publications have described strategies for developing and evaluating cancer biomarkers, focusing mainly on biospecimenderived biomarkers -that is, those derived from patient tissue or biofluids 4, [16] [17] [18] [19] [20] [21] . The processes of initial discovery, validation and qualification share many similarities for IBs and biospecimenderived biomarkers; however, substantial inherent differences exist between both biomarker types (Supplementary information S2 (table) ). The FDA and NIH have rec ognized this distinction and have outlined specific recommendations for image acquisition and analysis in IB development 22, 23 . Questions of how IB acquisition and analysis should be standardized, and how terminology should be harmonized have been addressed by numer ous academic, clinical, industrial and regulatory groups. These groups include the FDA 2, 24 , the US National Cancer Institute (NCI) through the Quantitative Imaging
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Maximum standardized uptake value is a parameter used routinely in clinical medicine to identify and quantify avidity of tracer uptake in PET studies.
K trans
Volume transfer co-efficient describes the transendothelial transport of low molecular weight contrast agent from blood vessels into the extravascular-extracellular space by diffusion. This imaging biomarker is commonly used in studies of antivascular agents, and measures a composite of blood flow, vessel permeability and vessel surface area. 25 and the Cancer Imaging Program phase I and II Imaging trials initiative 26 , the Quantitative Imaging Biomarkers Alliance (QIBA) 27, 28 , the American College of Radiology Imaging Network (ACRIN) 29 , the European Society of Radiology (ESR) 30 , the European Organisation for Research and Treatment of Cancer (EORTC) through the QuICConCePT consor tium 13, 31 , the European Association of Nuclear Medicine (EANM) 32 , the International Society for Magnetic Resonance in Medicine (ISMRM) 33 and Cancer Research UK (CRUK) 34 . Their efforts have produced consensus guidelines for the acquisition and analysis of several IBs [33] [34] [35] [36] [37] . Many of these organizations also have high lighted the need for a detailed validation and qualifica tion roadmap to improve IB translation 38, 39 . Recognizing this need, representatives from CRUK and the EORTC, together with other assembled experts in radiology, cancer imaging sciences, oncology, biomarker develop ment, biostatistics and health economics, have formu lated an Imaging Biomarker Roadmap for Cancer Studies (FIG. 2) . In this Consensus Statement, we outline this roadmap and identify specific considerations for IB vali dation and qualification, providing illustrative examples of IBs in various stages of development. From this frame work, we provide 14 recommendations to accelerate the successful clinical translation of effective IBs, as well as the devalidation 40, 41 of IBs that lack utility.
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Current uses of imaging biomarkers
An IB is a measurement derived from one or more medi cal images. Many IBs are used routinely in healthcare (TABLE 1) BOX 4) , demonstrating that imaging can be necessary to guide the choice of therapy for individual patients.
IBs frequently add value in cancer research (TABLE 1) . The use of IBs can enable the measurement of patient response to treatment before a survival benefit is observed, which can subsequently lead to early regulatory approval of new drugs 49 
. IBs can indicate the pres ence of drug targets and target inhibition, for example by proving receptor occupancy 50 (Supplementary informa tion S3 (box)). IBs have the unique potential to provide serial noninvasive mapping of tumour status during treatment. For example, absolute values of 18 FFDG PET maximum standardized uptake value (SUV max ) at baseline, or changes in this value observed early during treatment have been used for proofofmechanism and proofofprinciple 51 in drug development
, or to demonstrate nonspecific responses to treatment 52 54 . The use of IBs has led to improved margins of radiotherapy dose delivery 55 
and surgical margins 56 . Many more IBs used to measure tumour anatomy, morphology, pathophysiology, metabolism or molec ular profiles are being developed in order to study the hallmarks of cancer 57 (Supplementary information S8 (figure) ). Fourth, one imaging measurement can support multiple distinct IBs. For example, 18 FFDGPET has improved disease sta ging in patients with nonsmallcell lung cancer, lymph oma or melanoma by facilitating the identification of nodal and distant metastases 62 . In this case, the IB is clinical TNM stage, which is defined using CT and PET data rather than using CT data alone
. Similarly, systems such as PERCIST (for all solid tumours) 63 and the Deauville five point system (for lymphoma) 64 aim to improve the assessment of response criteria by incorporating PET data, but produce an ordered cat egorical IB -namely objective response
. This approach is conceptually different from quantifying absolute values of 18 FFDGPET data to derive putative cutoff points subsequently used to identify patients with poor prognosis 65 or evidence of specific pathway modulation in a clinical trial of an investigational new drug 66, 67 
Many quantitative image measurements comprise continuous data, which must then be categorized to facil itate clinical decisionmaking. Clinicians often decide between two or more alternative treatment options for each patient, informed by whether a biomarker value is above or below a cutoff point. For example, cancer therapyrelated cardiac dysfunction has been defined as LVEF reduction of ≥10 percentage points to a value below normal (53% for adults; BOX 3) . Clear guidelines detailing how scintigraphy or 2D echocardiography should be performed have been established for this IB of toxicity for use in healthcare 47 . In distinction, other healthcarerelated IBs (such as clinical TNM stage and objective response) are measured as ordered categorical variables. In this case, the boundary between several cat egories is defined by cutoff points; alternatively, catego ries can be combined to create a single cutoff point (for example, to select, continue or stop therapy).
In research applications, data are often interpreted as a continuous rather than used in a categorized way. 53 .
Specific considerations for IBs
IBs and biospecimenderived biomarkers differ in sev eral important aspects, limiting the relevance to IBs of previous roadmaps (designed for biospecimen derived biomarkers 13, 71 ; Supplementary information S2 (table)). The performance of imaging devices of different makes and models installed in different clinical centres can vary considerably. These devices are designed, approved, maintained, and operated to provide images 38 that diagnostic radiologists, nuclear medicine physicians and other clinicians interpret, often with little need to quantify the data obtained. Innovation is largely driven by competition to improve image quality and the user interface; vendors and purchasers often have only sec ondary interest in how improvements in image quality will affect quantification or standardization of IBs. The measurement of many IBs requires the administration of tracers or contrast agents (for example, diagnostic drugs, usually investigational or offlabel), the devel opment and availability of which are uncertain. Many steps in IB validation require a new prospective clinical trial; whenever investigational tracers or contrast agents are involved, the high burden of regulation can cause significant delays in this process.
Many IBs do not purport, even in principle, to measure any underlying analyte, making traditional approaches to assay validation seen with biospecimen derived biomarkers problematic. For example, dilution linearity and reagent stability -important performance characteristics for biospecimenderived biomarker assessment 12 -cannot be assessed for biomarkers based on analysing medical images, such as texturebased IBs. The measurement validity of such IBs depends substan tially on events that occur while the patient is coupled to the imaging device. Thus, the role of central reading laboratories in data processing is minor in comparison with biospecimenderived biomarkers 4 .
The imaging biomarker roadmap Biomarkers cross the two translational gaps by passing through a series of domains (discovery, or domain 1; validation, or domain 2; and qualification with ongoing technical validation, or domain 3) that address different research questions. This process follows two parallel and complementary tracks: in one track, technical (assay) performance is examined by addressing whether the biomarker is measurable precisely and accurately, and The imaging biomarker (IB) roadmap differs from those described for biospecimenderived biomarkers. For imaging, the technical and biological/clinical validation occur in parallel rather than sequentially. Of note, essential technical validation occurs late in the roadmap in many cases (such as full multicentre and multivendor reproducibility). Definitive clinical validation studies (IB measured against outcome) are deferred until technical validation is adequate for large trials. In the absence of definitive outcome studies, early biological validation can rely on a platform of very diverse graded evidence linking the IB to the underlying pathophysiology. Cost-effectiveness impacts on the roadmap at every stage, owing to the equipment and personnel costs of performing imaging studies. Technical validation and cost-effectiveness are important for IBs after crossing the translational gaps because hardware and software updates occur frequently. Therefore, technical performance and economic viability must be re-evaluated continuously. SOP, standard operating procedure. Image reproduced from http://www.cancerresearchuk.org/ sites/default/files/imaging_biomarker_roadmap_for_cancer_studies.pdf. whether it is widely available in all geographical terri tories. In the other track, biological and clinical per formances are examined by addressing whether the biomarker can be used to measure a relevant aspect of biology or predict clinical outcome. In reality, no bio marker is perfectly validated. Instead, strategies must be defined to identify, mitigate and quantify the uncer tainty, risk and cost associated with any given biomarker in making research or clinical decisions [72] [73] [74] . The nature of these activities and the sequence in which they are combined constitutes a 'biomarker roadmap' .
In biospecimenderived biomarker roadmaps, tech nical (assay) validation commonly occurs early in order to produce a 'lockeddown biomarker' -that is, the data acquisition and analysis pathways used to measure the biomarker are fixed. In many cases, this stage is followed rapidly by biological and clinical validation because the lockeddown biomarker enables widespread evaluation across multiple sites 4, 18 . For IBs, several key aspects of technical validation (such as multicentre reproducibil ity) must be addressed at a relatively late stage, unlike biospecimenderived biomarkers. Studies might address both technical and biological validation concurrently, but progress down each track might be quite independ ent. As evidence for validation accumulates, a third track of costeffectiveness must be considered, because IBs must not only demonstrate an association with health benefits, but also demonstrate 'value for money' when compared with the use of clinical information alone or with alternative biofluidbased in vitro diagnostics 75 .
Imaging biomarker discovery -domain 1
Most biospecimenderived biomarkers are molecular features found in the genome, transcriptome, proteome or metabolome that can be chosen rationally to address unmet needs in cancer medicine. This selection approach , volume transfer coefficient; LVEF, left ventricular ejection fraction; MARIBS, magnetic resonance imaging in breast screening; MTD, maximum tolerated dose; mTOR, mechanistic target of rapamycin; NA, not applicable; NICE, National Institute for Health and Care Excellence; PI3K, phosphoinositide 3-kinase; SPECT, single-photon emission computed tomography; SUV max , maximum standardized uptake value; US, ultrasound; XRT, X-ray computer tomography.
Double baseline studies
Biomarker precision can be assessed by measuring on multiple occasions and calculating the repeatability or reproducibility of the parameter. Typically, this precision is achieved by measuring the biomarker twice at baseline in the absence of any treatment effects.
has also inspired the rational design of several novel targeted nuclear medicine or optical imaging tracers 76 . Many of the most valuable IBs, however, have had a con voluted genesis through unanticipated discoveries in the physical sciences (chemistry, computing, engineering, mathematics or physics) being matched to unmet medical needs after initial discovery, and then developed further.
Technical validation -domains 2 and 3
Complete technical validation is achieved when an IB measurement can be performed in any geographical location, whenever needed, and give comparable data. Technical validation does not address whether the IB measures underlying biology, or relates to clinical out come and/or utility, but it can have a major influence on subsequent attempts at qualification because IBs with lim ited availability or poor reproducibility cannot sensibly undergo further clinical evaluation in large multicentre trials.
Precision. Repeatability and reproducibility are related measures of assay precision. Repeatability refers to meas urements performed multiple times in the same subject (in vitro and/or in vivo) using the same equipment, soft ware and operators over a short timeframe, whereas reproducibility refers to measurements performed using different equipment, different software or operators, or at different sites and times 77 , either in the same or in different subjects.
Different intended applications require different levels of evidence for precision 3 . For example, single centre repeatability might be sufficient to validate a PD or monitoring IB in an early phase clinical trial restricted to that site 53 . Conversely, screening, diagnostic, prognostic and predictive IBs with putative use in whole populations require evidence of reproducibility across multiple expert and nonexpert centres before they can be considered technically valid. Such multicentre validation requires complex and costly studies 13 . Repeatability analysis should be performed early in IB development. Repeatability estimated from studies using rodents can seem unfavourable because, in some models, tumours can grow considerably within a few hours 78 , but useful data can be gained in slowgrowing rodent models. Definitive repeatability analysis is best assessed in studies with humans, and should be performed at each centre that evaluates the IB anew, because reliance on historical or literature values is a source of error. Test performance is known to vary between sites, and is influenced by scanner performance, and organ site studied (for example, precision is better in brain lesions 79 compared with liver or bowel lesions [80] [81] [82] ). Physiological variations between individuals (depending on factors such as caffeine, nico tine, alcohol or concomitant medication) can also alter IB values 83 . Multicentre studies involve different research insti tutions that usually utilize devices supplied by different vendors. These devices are broadly equivalent for clinical radiology purposes, although they often have important hidden differences that affect IB acquisition and analysis (Supplementary information S2 (table)). These factors do not preclude multicentre technical assessment of IB pre cision, but values might not be as reproducible as those derived in fewcentre or singlecentre studies 84 
Supplementary information S4 (box)).
Unfortunately, despite the scientific benefits associ ated with double baseline studies, the time and financial cost of performing such studies often deters investigators and funders from incorporating repeatability or repro ducibility evaluations into study protocols. TNM is also predictive in some settings. In prostate cancer, clinical TNM stage distinguishes localized disease (T1-2 N0/Nx M0) from locally advanced disease (T3-4 any N M0; or any T N+ M0). This imaging biomarker (IB) is prognostic because patients in the former group have worse outcomes than those in the latter group. The same IB, however, is predictive of benefit for bicalutamide monotherapy, because this treatment only benefited patients with locally advanced disease in a large randomized controlled trial, leading to approval of the drug in the UK 146 . This IB has crossed the two translational gaps in biomarker development and is used daily in clinical practice.
TNM staging of a patient with stage IV non-small-cell lung cancer (T2 N0 M1) identified by a | T2 lung tumour on CT, b | no evidence of local nodal involvement on PET-CT, and c | brain metastases on MRI. 
Biological/clinical validation -domain 2
The terms 'biological validation' , 'clinical validation' and 'clinical utility' describe the stepwise linking of biomarkers to tumour biology, outcome variables and value in guiding decisionmaking, respectively. Clinical validation requires demonstration that the biomarker merely relates to a clinical variable and, therefore, is less difficult to establish than clinical utility (but also less meaningful) 86 . Clinical utility is achieved when the bio marker leads to net improvement of health outcomes or provides information useful for diagnosis, treatment, management, or prevention of a disease 10, 88 . The REMARK guidelines 89 45 . Morerigorous criteria must be met to validate an IB as a triallevel surrogate end point to completely replace a wellestablished clinical trial end point. The Prentice criteria 92 describe idealized conditions for demonstration of surrogacy, which unfortunately are rarely achieved and would typically require extremely large datasets 93 . Approaches for surrogate validation more pragmatic than the Prentice criteria involve the application of metaanalysis methods to a collection of large or moderatesized datasets that measure both the putative surrogate biomarker and the definitive clini cal end point 94 . These metaanalytic approaches often require some degree of IB standardization in order to combine datasets in a meaningful manner. Some IBs have been wellstandardized (such as the RECIST 1.1 objective response), whereas others (for example, DCE MRIderived K trans53 ; BOX 6) have not. Large prospec tive multicentre studies relating IBs to an outcome can only be initiated when exhaustive technical validation has established multicentre IB precision and accuracy. Clinical utility (and sometimes, validation) necessar ily happens late in the IB roadmap; therefore, alter native validation strategies must be sought for many novel IBs. Biological validation can be approached 45 or similar criteria using imaging techniques alongside biospecimen-derived and clinical measurements (see figure below) . Response criteria require a great level of detail and therefore, such measurements can be reproduced robustly.
Objective response has crossed the two translational gaps in biomarker development and is used daily in clinical practice, as well as by regulators to approve new drugs for full market approval and accelerated approval 49 . Several research studies have attempted to optimize the definition of objective response for specific tumour-therapy combinations. Examples include incorporating 18 F-FDG-PET data into response assessment in lymphoma, measuring the peak of the standardized uptake value (SUV peak ) in PERCIST 62 and the peak of the standardized uptake value (SUV max ) in the Deauville criteria 63 , or adapting thresholds required to define partial response and partial disease as described in the Choi criteria for assessing response of GIST to imatinib therapy 148 . In all of these cases, however, the biomarker remains the objective response.
When a new version of a biomarker is tested against an existing version (for example, PERCIST and RECIST 1.1 definitions of objective response), and if the possibility of comparing paired measurements from each patient (with established and fixed acquisition and analysis methods) exists, then assessment on whether the new method better predicts a relevant clinical end point (such as overall survival) can be carried out. However, information can also be derived from measuring concordance between the two methods on a per-case basis (with a weighted kappa statistic) because both methods might measure different aspects of tumour biology or have different error sources, but can have similar ability to predict a clinical end point. by accumulating a platform of evidence linking the IB to meaningful biological features, and response to therapies with wellstudied mechanisms of action 71 . These principles -outlined by Bradford Hill 93, 95 (Supplementary information S9 (box)) -establish evidence for IB performance on the basis of scientific coherence, specificity, strength of association, effect gradient, temporality and consistency.
If the Bradford Hill criteria are adopted, early preclin ical imaging-pathology correlation studies 5, 96 provide an important component of the platform of evidence because wholetumour histopathology is rarely possible in patients. Studies conducted with animals enable clin ically relevant IBs to be related to fundamental bio logi cal processes that can only be measured with invasive techniques. For example, the relationship between DCE MRIderived K trans and tumour blood flow rate (a fun damental measure of response to antivascular agents) was investigated using a terminal radiotracerbased technique in rat tumour models 97 . Preclinical studies also enable the examination of the therapeutic doseresponse relationship at different time points in a range of tumour models. Of note, however, pathophysiological assays are often considered as a 'reference standard' , but are also biomarkers and thus imperfect, and also subject to sampling bias. Thus, some 'reference standard' tests might not enable the prediction of survival, or relate to the intended biological process. Moreover, precise pathophysiological correlates of some IBs might not exist, or can be almost impossible to obtain 13 . Evidence of imaging-biology correlations and early response to therapies can provide sufficient biological validation to establish IBs as useful for PD assessments or monitoring response in early phase clinical trials, even in the absence of compelling outcome data 53 . The IBs 18 FFDGPET SUV max and K trans (BOXES 5,6) are illustra tive of how IBs can cross translational gap 1 to guide decisionmaking for subsequent studies. For example, the biologically active dose for the antivascular agent ZD6126 calculated according to K trans measurements 98 was shown to be greater than its maximum tolerated dose, effectively halting further clinical development of this agent. In other studies, K trans data informed of the biologically active dose for cediranib 99 and the optimum scheduling for brivanib 100 
.
Cost-effectiveness -domains 2 and 3
To be translated into the clinic, IBs must provide good 'value for money' and compare favourably with biospecimen derived biomarkers resulting from technolo gies, such as 'liquid biopsies' of isolated circulating tumour cells or cellfree DNA. In the research setting, the value added by testing a key hypothesis (with an IB) should be greater than the cost of performing the study. In healthcare, the economic test is harsher, because even wellvalidated IBs will not cross translational gap 2 unless they offer an advantage in terms of cost per quality adjusted life year (QALY) gained 13 . Initially, translating IBs into the healthcare setting is costly and timeconsuming 101 . Studies in early stages of IB discovery and validation can access conventional biomedical research funding streams, whereas evidencegathering studies to support IB qualification can be difficult to fund. For example, largescale multicentre reproducibility studies can be unattractive to research funders if seen as 'incremental' and, unless such studies create exploitable intellectual property, they are not attractive to commercial spon sors. One approach to solve this problem is to assemble consortia of commercial and notforprofit stakehold ers, such as the QuICConCePT consortium 13, 31 , QIBA 28 and QIN
102
, to undertake multicentre validation steps to meet the collective needs of the community.
Initial IB translation requires largescale funding by government, charity or industry, or commercialization of the IB by an imaging company (for example, a major scanner manufacturer in the case of hyperpolarized 13 CMRI/MRS), or by a startup business focused on a specific technique or IB. This strategy requires careful assessment of the likely risk-benefit of the development process, and strong intellectual property positions to ensure likely financial return on the imaging device, agent or biomarker 38 . Complex economic considerations are related to IBs developed as companion diagnostics associated with a specific therapeutic. Such IBs might be
Box 3 | Left ventricular ejection fraction -safety prognosis and monitoring IB
Many well-established (for example, radiotherapy, doxorubicin or trastuzumab) and recently introduced (for example, tyrosine kinase inhibitors) anticancer therapies are associated with a substantial risk of cardiotoxicity 149 . Reduced left ventricular ejection fraction (LVEF) is well-established in cardiovascular medicine as prognostic of cardiac outcomes, measured by various methods, such as transthoracic ultrasonography, scintigraphy and, in research studies, using MRI. Guidelines for the use of LVEF in the care of patients with cancer have been defined, with a consensus in defining cancertherapeutics-related cardiac dysfunction as a decrease in LVEF of >10%, confirmed with repeated imaging 47 . This imaging biomarker (IB) has crossed the two translational gaps in biomarker development and is used widely in care of cancer patients; FDA-approved labels for therapies such as lapatinib, sunitinib, doxorubicin or trastuzumab 150 all require measurement of LVEF. ; BOX 4), the market for the companion diagnostic disappears.
Qualification -domain 3
The term 'qualification' has different scientific and regu latory meanings. Generally, qualification is an evidentiary process of linking a biomarker with biological processes and clinical end points intended to establish that the bio marker is fit for a specific purpose 96, 103, 104 . For example, the use of IBs qualified as prognostic would enable the enrichment of a clinical trial population with patients at the highest risk of experiencing a clinical event, thus increasing the efficiency of the trial 105 . Such IBs have to be clinically validated to show their association with an outcome, but might not necessarily be associated with clinical utility for decisionmaking in healthcare. In dis tinction, the same IB could potentially be qualified for prediction of patient response (or lack of response) to a particular therapy based on evidence that the treatment effects in biomarkerpositive patients differ from those in biomarkernegative patients (for example, superior out come with experimental therapy in biomarkerpositive patients versus biomarkernegative patients) 106 . The IB might be used for enrichment or stratification of patient populations in clinical trials and, if the trial is successful, such IB could be further developed into a companion diagnostic with established clinical utility for identifying patients likely to benefit from the new therapy.
Qualification requires demonstration of fitness for a particular purpose and, therefore, an IB might need to be evaluated in several scenarios to justify a broad claim of qualification. Hence, the IB might become qualified for one particular use (such as for a cancer type or a certain drug class), but not for others. Nevertheless, when a biomarker is qualified in multiple settings (for example, different tumour types, different therapies or different research questions), then the process of quali fication for a new application can be expedited because most of the necessary validation requirements are likely to have been fulfilled 107 . 'Regulatory qualification' is a morespecific term that describes a framework for the evaluation and accept ance of a biomarker for specific use in regulatory deci sionmaking 108 (Supplementary information S1 (table) ). Examples include new drug approvals or safety monitor ing. This framework for regulatory qualification is not a formal requirement for a drug developer who merely wishes to 'qualify' an IB to support a proofofmechanism or a doseselection decision.
Roadmap application
With this Consensus Statement we aim to accelerate IB translation. For this purpose, we have produced 14 key recommendations
, accompanied by a detailed imaging biomarker roadmap for cancer studies (FIG. 2) . Together, the roadmap and recommendations provide a framework for understanding how to examine qualitative and quantitative IBs at all stages of their validation and qualification. Herein, we identify the key steps required to achieve these goals, recognizing the important differ ences between IBs and biospecimenderived bio markers. No biomarker is expected to be perfect; instead, this roadmap provides a tool to assess the current evidence for technical and biological and/or clinical performance of any given IB at any stage of development. The limitations of each IB can be identified, quantified, documented and made publicly available. In the process of creating this roadmap, we have identified several potential obstacles in the clinical translation of putative IBs.
Key recommendations
Recommendations 1-2 -grant submissions and study publications. Proposals for funding to support IBrelated studies should state clearly how these will advance IB vali dation or qualification. Resulting journal publications should state explicitly how these aims have been achieved (recommendation 1). Study design, protocols, quality assurance processes and standard operating procedures
Box 4 | 99m Tc-etarfolatide -companion diagnostic IB with regulatory approval
Nuclear medicine imaging biomarkers (IBs) can help to identify the presence or absence of a cancer phenotype, acting as binary categorical biomarkers, similarly to genomic identification of mutation status. For decades, 131 I-radio-iodine scintigraphy has enabled the identification of local and distant disease in patients with thyroid cancer, as a subjective radiological assessment, rather than by deriving an IB 151 . Conversely, radiolabelled somatostatin receptor analogues are used in scintigraphy (for example, 111 In-pentetreotide octreotide) 152 and in PET-CT (for example, 68 Ga-dotatate) 153 to identify neuroendocrine tumour sites; such IBs are categorical, defined by a maximum standardized uptake value (SUV max ) in the target lesion that exceeds the background SUV max . If the scan is positive, the IB alters clinical management because ablative treatment is given (see figure below) .
The European Medicines Agency (EMA) and the FDA have authorized new personalized medicines with a label mandating a blood-based, tissue-based, or imaging-based companion diagnostic. As an example of how IBs could be companion diagnostics in oncology, the EMA Committee for Medicinal Products for Human Use recommended FR+ (folate receptor-positive status assessed using 99m Tc-etarfolatide scintigraphy) for approval as a companion imaging diagnostic in patients with platinum-resistant ovarian cancer treated with vintafolide therapy. This recommendation was conditional on the outcome of the PROCEED trial of vintafolide, which reported negative results 154, 155 . This case set an important regulatory precedent for an imaging-based companion diagnostic.
A patient with a metastatic neuroendocrine tumour undergoing a diagnostic 68 Ga-dotatate PET-CT has a | multiple disease sites on fused coronal images, and b | maximum intensity projection. The patient then received therapeutic 177 Lu-dotatate, which enables demonstration of drug uptake at the disease sites, confirmed by SPECT-CT examination on c | fused coronal images and d | maximum intensity projection.
should be reported exhaustively by making full use of supplementary materials for research publications. The software used for image processing should also be reported and be made available once intellectual property rights have been addressed (recommendation 2). These two recommendations will result in the greatest possible confidence in the reported IBrelated data, will facilitate the conduct of statistically valid metaanalysis studies of imaging data, and will help investigators, reviewers, target audiences, funders and governments evaluate the risks associated with each IB for any given research or healthcare application.
Recommendations 3-7 -technical (assay) validation.
A compelling rationale supports the accreditation of clinical imaging laboratories as being competent for measuring a given IB (recommendation 3), in line with the standards set by the biospecimenderived bio marker community 4 . This approach has been adopted by the PET community when performing quantita tive 18 FFDGPET in clinical trials both in Europe and North America, focusing on performing regular equip ment calibration and quality assurance. Moreover, data acquisition, analysis and reporting standards have been adopted 32 . In Europe, this initiative has been driven by the EANM and endorsed by the EORTC to ensure that institutions involved in multicentre clinical trials adopt bestpractice procedures, and that quantitative reporting is harmonized across sites to improve reproducibility. Participants receive certification to distinguish them from nonparticipating institutions. Similarly, standard ization of DCEultrasonography 109 and LVEF measure ments 47 have been addressed by expert consensus. In the USA, the NCI evaluates performance of dynamic and static PET, volumetric CT and DCEMRI in partnership with the ACRIN 29 . All NCIdesignated cancer centres have been certified for measurement value equiva lence, with ongoing annual inspection to provide regu lation 39 . This certification involves the incorporation of IBs in clinical trial design and requires evaluation of the performance of imaging sites by the NCI Clinical Trials Network 26 . Site accreditation is an important step towards improving technical performance in multicentre studies, but must reflect widely sought academic consensus, become adopted by international societies, and receive the backing of funders, industry and regulators for such accreditation to have value. Accreditation must simul taneously promote standardization and harmonization of IBs for multicentre use, while accommodating studies led by investigators who have scientific freedom to fur ther develop and optimize IBs. To achieve this optimi zation, bestpractice guidelines for each widely used IB (or related family of IBs) must be updated and reviewed regularly (recommendation 4), because biomarker drift is inevitable owing to technological advances in scanner performance (for example, clinical trials with ongoing data collection can be affected by hardware and soft ware upgrades). Suitable statistical methods, such as multivariate linear regression analysis and other more complex statistical approaches, must be used to adjust for changes in IBs during ongoing studies (for example, defining prechange and postchange data).
IB precision must be demonstrated early in IB develop ment through singlecentre repeatability studies, or few site reproducibility studies (recommendation 5). This F-FDG-PET signals map the spatial variation in glucose uptake, which is increased in tumours owing to their high rate of glycolysis 32, 35 . Many therapies reduce glucose uptake, including established cytotoxic chemotherapy agents 156 and antiangiogenic agents 66, 157 ; for such therapies, Δ 18 F-FDG-PET SUV max is a nonspecific IB for monitoring treatment response.
• Conversely, over 20 studies of PI3K-AKT-mTOR pathway inhibitors have used Δ
18
F-FDG-PET SUV max as a pharmacodynamic (PD) IB to measure specific and very acute effects of target and pathway inhibition 67, 158, 159 . In these studies, Δ 18 F-FDG-PET SUV max provides proof-ofmechanism in the pharmacological audit trail 5 as a specific PD IB, because PI3K plays a central role in regulating cell functions, including metabolism, in conjunction with downstream kinases, such as AKT and mTOR 160 (see opposite image).
• The spatial distribution of 18 F-FDG-PET SUV max can be mapped and used as an IB in radiotherapy treatmentplanning. A randomized phase II trial is comparing isotoxic dose-escalation and dose-boost to tumour regions with >50% of the SUV max value 55 . If the results of this study are positive, it could support the use of functional imaging in radiotherapy planning and adaptive therapy during treatment.
Further standardization is necessary for the IB to cross translational gap 2.
Clinical trial of the PI3K inhibitor pictilisib 67 shows >30% reduction in the Nature Reviews | Clinical Oncology Nature Reviews | Clinical Oncology assessment is particularly important when testing the ability of an IB to measure the effect of therapeutic inter vention. The choice of performance metric is important; for example, the coefficient of variation assumes that the standard deviation is approximately proportional to the mean. If studies of repeatability are performed under mul tiple conditions (such as imaging patients across different groups), then a plot of the standard deviation versus mean should be examined to determine whether this propor tionality is valid. In most imaging studies of repeatability, only two replicates are acquired for each patient and thus, a Bland Altman plot will enable the evaluation of whether or not the mean of the measurements influence on variance, providing overall limits of agreement 110 .
Once the IB is shown to have sufficient technical and biological validity to cross translational gap 2, multicentre reproducibility must be evaluated (recommendation 6). Some studies have measured IB multicentre reproducibil ity (for example, DCECT evaluation of ovarian cancer 111 ), but these are rare exceptions. The recruitment of patients with cancer to attend for scanning on devices at multi ple centres is seldom possible and thus, studies usually require the use of data from different patients, scanned on different machines. Considerable centrespecific dif ferences might exist regarding devices, contrast agents and tracers, and software. This variability must be accounted for when considering multicentre reproducibility. Mixed effects modelling provides a statistically robust approach to maximising data inclusion, while acknowledging inevitable slight inconsistencies in the data 112 . Dataanalysis strategies must be developed for multi centre studies (recommendation 7). Analysis led by one central site can reduce data variation for studies with a moderate number of participating sites 113, 114 . As IBs transition towards crossing gap 2, however, using one central site is inappropriate for IBs that will eventually be analysed at many cancer centres once the IB has been adopted in healthcare. To facilitate this transition, sites should compare their own technical performance against a central analysis, similarly to the assessment of objective responses in oncology trials.
Recommendations 8-11 -biological validation and clinical validation.
Clinical validation occurs relatively late in the development process for most IBs compared with biospecimenderived biomarkers 71 . Extensive preclinical studies can provide wellcontrolled data to examine the relationship of the IB to pathology, and the IB to the effects of interventions, and therefore are strongly encouraged (recommendation 8). The choice of experimental model is an important consideration. Tumour xenograft models in immunodeficient mice are wellstudied and have reproducible growth charac teristics 115 , and can be ideal for initial IB development, but tumour models that better portray the relevant bio logical characteristics found in human cancers are also needed 116, 117 . Firstly, in situ tumours, or those implanted into their orthotopic site often better recapitulate the local microenvironment of human tumours 117, 118 . Secondly, syngeneic models, with intact immune sys tems, are essential for some studies (for example, for the evaluation of IBs for immunotherapies). Thirdly, appropriately geneticallyengineered mouse models can have lesions that accurately mimic human tumours 119 , an approach that can facilitate coclinical trials in which preclinical studies are run in parallel with clinical trials in order to identify likely responders to targeted ther apies 118, 120 . Finally, models derived from patient tissue (PDX models) 121 or circulating tumour cells (CDX models) 122 offer potential insights into developing per sonalized therapeutic regimens 123 . The biological valida tion of IBs must incorporate the use of these models once proofofconcept has been demonstrated in xenograft models. When possible, IBs should then be validated in clinical studies 124 , in order to confirm imaging-biology relationships in humans. Adaptive trial designs can be use ful for early stage IB studies 125 . Samplesize reestimation can be performed in those studies in which limited relevant data inform on sample size 126 . Similarly, group sequential design 127 can provide flexibility in the num ber of animals or patients entered into a study. Such approaches can ensure adequate power with small sample sizes -if effect sizes are suitably large -and, therefore, can make imaging studies more affordable 128 . 161, 162 . Change in K trans from baseline (ΔK trans ) and similar metrics (such as ΔIAUC 60 (integrated area under the curve at 60 seconds)) have been used in >100 early phase clinical trials and academic-led studies of antivascular agents to demonstrate proof-of-principle 51, 82 , as well as to identify optimum drug doses and schedules 53 (see figure below) . ΔK trans has crossed translational gap 1 as part of the pharmacological audit trail 5 , and has assisted in the development of antiangiogenic drugs by helping to select doses for cediranib 99 and other agents 53 , and determining the schedule for brivanib 100 . This IB has also contributed to the decision to halt further development of the antivascular agent ZD6126 by demonstrating that the biologically active dose was greater than doses that induced toxicity 98 . At present, substantial interlaboratory variation in DCE-MRI acquisition and analysis mean that absolute values of K trans can vary by an order of magnitude across centres 163 . This limited technical validation has prevented IBs based on absolute values of these parameters from crossing the translational gaps to be used as prognostic IBs Improved methods for imaging-biology correlation are needed for IB biological validation (recommenda tion 9), because currently available methods often fail to account for extensive spatial heterogeneity in the IB 129 , including early robust imaging-pathology correlations through comprehensive series of studies with patients and relevant animal models (including genetically engineered mouse models, syngeneic models and orthotopic and/or in-situ tumours). Rationale. Biospecimen-derived biomarkers can often be evaluated rapidly against survival rates using biobanked samples. This possibility is uncommon for IBs, unless the IB is derived from images acquired routinely in healthcare. 9. Improved capabilities should be developed for accurate imagingpathology correlation, including whole-tumour 3D analysis and alternative 'gold standards', such as biospecimen-derived readouts. , led by the US National Cancer Institute, illustrate possible solutions to these problems. Furthermore, image repositories enable rapid evaluation of IBs derived from existing data. 11. All true-negative, false-negative and false-positive data obtained in studies with either animals or humans should be published.
Rationale. Reluctance to publish negative findings results in considerable publication bias and risks overstating the degree of IB validation.
Qualification
12.
Definitive studies linking IB to clinical outcomes must be prospective, in relevant patient populations, and adequately powered. Novel study designs are encouraged. Rationale. Many IB studies are underpowered for sensitivity, specificity and survival data. Study populations should not be dominated by highly selected patients who are more able to undergo thorough complex imaging protocols than the general patient population.
Cost-effectiveness 13. New models for funding and regulation should be developed for investigational devices and tracers and/or contrast agents that lack commercial viability as diagnostic products in healthcare systems, but have value in the research setting as IBs.
Rationale. Research related to many valuable IBs involves specialized devices, tracers and contrast agents that are not commercially viable as diagnostic products. Regulatory hurdles are rightly much higher for marketing approval than for investigational use; however, precedent set by the PET community has maintained availability of many investigational tracers for research use even with limited or no marketing prospects. 14. Outcome studies should include health economic considerations.
Comparisons of cost per quality-adjusted life year (QALY) should be performed between imaging and competitor biospecimen-based biomarkers.
Rationale. IBs are perceived to be costly; thus, a clear QALY advantage should be demonstrated. measurements 91, 130 . The use of appropriate statistical methods is required to define associations between imaging and pathology measurements. Spearman's rho or Kendall's tau rank correlation coefficients enable the com parison of IB values to reference standard pathology read outs within a cohort; however, if these two measurements (or transformations of these variables, such as logarithms) relate linearly to one another, regression models provide estimates of biases and the scale of the relationship.
IB studies often generate rich datasets that can be col lected and banked for future reuse. These data include raw images, processed images and parameter maps, ancillary files (such as regions of interest, mask files, and stored header information detailing scan parameter settings), and essential patient metadata covering demo graphics, treatment history and clinical outcome (such as response, progressionfree survival and/or overall survival). Useful dataarchiving systems require finan cial support; collaboration between multiple academic, industry and funding partners; and ongoing curation and active management -as exemplified by the NCI Informatics Technology for Cancer Research platform 131 .
Technological advances (such as cloudbased solutions) must be accompanied by suitable information govern ance arrangements, potentially crossing international legal and regulatory frameworks 102 , and by commitment from funders to resource these initiatives.
Creation of animal and human cancer image reposito ries, following the lead of organizations including the NCI and the ESR 132 , is strongly encouraged (recommendation 10) to enable rapid testing of new analyses by researchers from different institutions. In some cases, this approach can even lead to a reduction in the number of animal experiments (in line with the 3Rs of animal welfare in cancer research 116 ) or in the number of new patients recruited. Standardized data collection, analysis and archiving are required to support multisite clinical trials 102 . Complete and transparent study reporting is essen tial to avoid selective reporting bias and publication bias (recommendation 11). Results of all prespecified analyses (secondary analyses as well as primary analyses) should be reported, regardless of whether they are consistent with expectations, or whether they achieve statistical sig nificance 133, 134 . Highlighted exploratory analyses (either prespecified or post hoc) should be accompanied by a description of all other exploratory analyses performed. This strategy will moreaccurately reflect the potential for falsepositive and falsenegative findings. Adherence to these principles of reporting will help to eliminate the distortion of research findings resulting from selective reporting and failure to publish negative studies. These biases can also be reduced by registering studies and detailing their hypotheses on publically available websites (such as ClinicalTrials.gov) before the study is initiated or before outcome data are unblinded 89, 135 . Recommendation 12 -qualification. Robust study design and predefined statistical analysis plans are vital to ensuring that the highest quality evidence is available to qualify IBs. Latestage multicentre clinical trials should be powered adequately to demonstrate clinically useful effects. At present, few IBs are rigorously validated or qualified as prognostic for quality of life, progressionfree survival or overall survival 136 . Appropriate statistical methods (for example, control of the falsediscovery rate and crossvalidation techniques 137 ) are needed to avoid spurious findings and overfitting caused by measurement of large numbers of image parameters relative to numbers of patients -a common problem in several published biospecimenbased biomarker studies 138 . Efficient study designs should be pursued, for example, in studies of diag nostic accuracy 135 or test impact, in which each patient is regarded as his or her own control; examples include add ing functional imaging to standard anatomical radiology in order to improve diagnosis 139, 140 . In laterstage clinical trials, several treatments can be tested concurrently in the same trial using enrichment or predictive IBs, as is the case of current molecular profilingbased studies 141 . This measure can increase recruitment efficiency, reduce costs, and accelerate achievement of primary end points 142 . Qualification requires rigorous and detailed statistical reporting standards. Screening and diagnostic accuracy IB studies should report sensitivity and specificity, results of receiver operating characteristic (ROC) curve analysis, and negative and/or positive predictive values 135 , whereas prognostic and predictive IB studies should report esti mated effect sizes, such as hazard ratios 89 . Estimates should be accompanied by measures of uncertainty (for example, 95% confidence intervals) as well as statistical significance. In studies in which predictive biomarkers are evaluated using randomized controlled trials, CONSORT guidelines should be followed 143 .
Recommendations 13-14 -cost-effectiveness. New models for funding and regulation should be developed for investigational devices, tracers and contrast agents, and software that have value as IBs in the research set ting, but lack commercial viability as a diagnostic prod uct in healthcare systems (recommendation 13). Imaging studies are perceived to be expensive and thus, integra tion of investigational IBs should be linked to exist ing radiological tests (addition of the IB to a clinically approved ultrasonography, CT or MRI examination, for example) whenever possible. Largescale studies should include healtheconomic considerations, including meas uring the costeffectiveness of IBs versus competitor tests (other IBs or biospecimenderived biomarkers) 144 ( recommendation 14).
Conclusions
Clinical imaging has transformed contemporary medi cine 145 . IBs have enormous potential to facilitate further advances in cancer research and oncology practice by accurately informing clinical decisionmaking, but must undergo rigorous scrutiny through validation and quali fication to achieve this end 13 . This process of evaluation enables investigators and consumers to make informed decisions about IB translation for each research and healthcare application 10 . The roadmap and recommen dations that we present herein will, if adopted, mark a change in the development and use of IBs in cancer research and patient management.
